Share This Page
Drug Price Trends for NDC 71288-0723
✉ Email this page to a colleague
Average Pharmacy Cost for 71288-0723
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BUPIVACAINE 0.25% VIAL | 71288-0723-52 | 0.04531 | ML | 2025-11-19 |
| BUPIVACAINE 0.25% VIAL | 71288-0723-52 | 0.04636 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71288-0723
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 71288-0723
Introduction
The drug identified by NDC 71288-0723 is a recently approved pharmaceutical product, with limited publicly available data on its commercial landscape, pricing strategies, and market potential. This report systematically analyzes the product’s positioning, competitive landscape, potential pricing trajectories, and market opportunities to support stakeholders in informed decision-making.
Product Overview
The National Drug Code (NDC) 71288-0723 is associated with [insert drug name, e.g., "Virexolm"], a [specify formulation, e.g., injectable/oral biological/small molecule] indicated for the treatment of [specify indication, e.g., metastatic melanoma, rheumatoid arthritis, etc.]. Approved by the FDA in [year], the drug targets [specific patient population or disease area]. The mechanistic advantage lies in [key innovation or differentiation—e.g., enhanced efficacy, reduced side effects, delivery method].
The drug’s entry into the market coincides with a paradigm shift in [relevant therapeutic area], driven by advancements in [diagnostics, delivery, biomarkers, etc.]. Its initial approval was supported by clinical trial data indicating [brief outcome summary—e.g., statistically significant improvements, safety profile, etc.].
Market Landscape
Therapeutic Area & Demographics
The drug operates within the [specify therapeutic area, e.g., oncology, autoimmune disorders, infectious diseases]. Market research indicates a [growth rate, e.g., CAGR of X%] for this sector over the next [time span], driven by [factors such as aging populations, prevalence increase, unmet needs].
The targeted patient demographic includes [e.g., adults aged 50+, patients refractory to existing therapies, pediatric populations], with an estimated [market size, e.g., 200,000 patients globally], forecasted to expand as [related diagnostic tests, disease awareness, reimbursement policies] evolve.
Competitive Landscape
The competitive environment features:
-
Existing therapies – [list major competitors, e.g., Drug A, Drug B, Drug C], with market shares ranging from [X]% to Y%. These therapies are characterized by [e.g., administration routes, efficacy, safety profiles, pricing].
-
Innovative entrants – Several pipeline candidates vying for regulatory approval, with [number] in late-stage development.
-
Differentiation factors – The new drug’s unique selling propositions include [e.g., improved efficacy, reduced adverse events, convenient dosing].
Market penetration depends on [regulatory approvals, pricing, physician acceptance, patient adherence].
Pricing Strategy and Projections
Current Pricing Landscape
As a newly launched or upcoming product, the current list price ranges between \$[X] and \$[Y] per [dose, treatment course, vial, etc.], based on [manufacturer disclosures, insurer reports, pricing databases like RED BOOK, SSR Health].
Given the typical escalation seen with innovative drugs, initial pricing tends to align with comparable products. For example, drugs in similar therapeutic categories have maintained prices of \$[X]–\$[Y] per unit or treatment course.
Factors Influencing Price Trajectories
-
Market penetration – As the drug gains acceptance, pricing might stabilize, especially if reimbursement terms are favorable.
-
Competitive pressures – Entry of similar or biosimilar products can exert downward pressure (average price erosion of 10-25% over 3-5 years).
-
Regulatory incentives and pricing policies – Price controls in key markets like the U.S., EU, or Japan influence long-term price stability.
-
Manufacturing costs & supply chain dynamics – Impact marginal price adjustments over time.
Future Price Projections (Next 5-10 Years)
Based on market trends, regulatory environment, and competitive landscape:
| Year | Estimated Price (per unit/treatment) | Rationale |
|---|---|---|
| Year 1 | \$[initial price] | Premium positioning due to novelty and clinical benefit. |
| Year 3 | \$[projected price, e.g., -15%] | Competitive entry and payer negotiations begin to influence pricing. |
| Year 5 | \$[projected price, e.g., 10-20% lower than Year 1] | Standard industry erosion, patent strategies, biosimilar entries. |
| Year 10 | \$[long-term projection] | Market normalization, increased competition, or potential price adjustments driven by biosimilars/biosuperiors. |
Pricing Factors to Watch
-
Reimbursement policies – CMS, private insurers, and international agencies influence attainable prices.
-
Value-based care adoption – Demonstrating superior clinical outcomes can sustain premium pricing.
-
Patient access programs – Managed care discounts, copay assistance, and subscription models could modify net price realizations.
Market Penetration & Revenue Forecasts
Assuming gradual adoption within the target demographic:
-
Year 1: Capture [X]% of the estimated [market size] patients, generating revenues of approximately \$[Y] million.
-
Year 5: Expansion to [Z]% market share, with revenues reaching \$[W] million.
-
Long-term: Revenue projections depend on pricing trends, patent exclusivity periods, and competitive landscape shifts. Conservative estimates suggest a compound annual growth rate (CAGR) of [X]%, reaching \$[target] by Year 10.
Strategic Opportunities & Risks
Opportunities
- Orphan drug designation (if applicable), granting market exclusivity and pricing premiums.
- High unmet medical needs and robust clinical data to support value-based contracts.
- Partnerships with payers, patient advocacy groups, or specialty pharmacies can accelerate adoption.
Risks
- Regulatory delays or changes, affecting market entry or reimbursement.
- Market saturation with biosimilars or next-generation competitors.
- Pricing pressures from expanded pipelines or government initiatives dictating drug prices.
Key Takeaways
- Market viability hinges on demonstrating clinical superiority, securing high-value reimbursement, and effective commercialization strategies.
- Pricing strategies should initially emphasize premium positioning complemented by contingent discounts and patient access programs.
- Long-term projections suggest a gradual price erosion influenced by competitor entry, regulatory shifts, and market expansion.
- Monitoring regulatory developments and stakeholder engagement is vital to optimize pricing and market share.
- Incorporating value-based models may provide sustainable revenue streams while aligning payer and provider incentives.
FAQs
Q1: What factors most influence the drug’s pricing trajectory? A: Reimbursement policies, clinical value demonstration, competition, and manufacturing costs heavily influence pricing projections. Building strong clinical evidence and payer relationships is central to maintaining premium pricing.
Q2: How might biosimilars or generics impact this drug’s market? A: Biosimilar entries can lead to significant price erosion, typically around 20-30% within 3-5 years, necessitating early differentiation and value demonstration.
Q3: What markets should stakeholders focus on beyond the U.S.? A: European countries, Japan, and emerging markets like China and India present growth opportunities, often with varying regulatory and pricing frameworks.
Q4: How does patent protection influence pricing and market share? A: Patent exclusivity supports higher prices and market share; patent expiration typically precipitates price reductions and increased competition.
Q5: What role does value-based contracting play in future pricing? A: Linking reimbursement to clinical outcomes can sustain premium prices, mitigate payer resistance, and foster long-term market stability.
References
- [Insert inline citation, e.g., "Market data sourced from SSR Health."]
- [Insert regulatory approval details from FDA or EMA.]
- [Industry reports on therapeutic area growth projections.]
- [Pricing benchmarks from RED BOOK or similar databases.]
- [Patent and exclusivity data from FDA or patent databases.]
Disclaimer: This analysis is based on current publicly available data and market trends. Actual outcomes may differ due to unforeseen regulatory, competitive, or market dynamics. Stakeholders are advised to conduct comprehensive due diligence tailored to their strategic needs.
More… ↓
